Amrize Ltd (NYSE:AMRZ – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seventeen research firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $63.00.
Several equities research analysts recently commented on AMRZ shares. Citigroup cut their target price on shares of Amrize from $76.00 to $66.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Oppenheimer set a $68.00 price target on shares of Amrize in a research report on Friday, May 1st. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Amrize in a research note on Monday, June 22nd. Morgan Stanley set a $63.00 price target on shares of Amrize and gave the stock an “overweight” rating in a report on Monday, June 22nd. Finally, Weiss Ratings cut shares of Amrize from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday.
Read Our Latest Report on Amrize
Amrize Price Performance
Amrize (NYSE:AMRZ – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Amrize had a return on equity of 9.84% and a net margin of 9.70%.The firm had revenue of $2.18 billion for the quarter. The company’s revenue was up 4.7% compared to the same quarter last year. Analysts expect that Amrize will post 2.74 EPS for the current year.
Amrize Cuts Dividend
The business also recently announced a dividend, which was paid on Wednesday, May 20th. Shareholders of record on Tuesday, May 12th were issued a dividend of $0.11 per share. The ex-dividend date of this dividend was Tuesday, May 12th. Amrize’s payout ratio is presently 21.05%.
Insider Buying and Selling
In related news, CEO Jan Philipp Jenisch purchased 21,417 shares of Amrize stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $49.67 per share, for a total transaction of $1,063,782.39. Following the transaction, the chief executive officer owned 1,724,999 shares of the company’s stock, valued at approximately $85,680,700.33. This represents a 1.26% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Nollaig Forrest acquired 2,000 shares of the stock in a transaction dated Friday, May 22nd. The shares were bought at an average price of $50.25 per share, with a total value of $100,500.00. Following the completion of the transaction, the insider directly owned 20,139 shares of the company’s stock, valued at $1,011,984.75. The trade was a 11.03% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 54,920 shares of company stock valued at $2,717,429 over the last 90 days. 0.54% of the stock is owned by corporate insiders.
Institutional Trading of Amrize
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC bought a new position in Amrize during the 2nd quarter worth approximately $265,000. M&T Bank Corp bought a new stake in shares of Amrize in the 2nd quarter valued at $205,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Amrize during the second quarter worth $3,870,000. Gabelli Funds LLC acquired a new stake in Amrize during the 2nd quarter worth about $1,083,000. Finally, AXA S.A. bought a new stake in shares of Amrize during the 2nd quarter valued at about $1,065,000.
Amrize Company Profile
Amrize AG focuses on building materials business in North America. The company was incorporated in 2023 and is based in Zug, Switzerland. Amrize AG operates independently of Holcim AG as of June 23, 2025.
Featured Articles
- Five stocks we like better than Amrize
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Amrize Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amrize and related companies with MarketBeat.com's FREE daily email newsletter.
